Education
About Us
Working with TipRanks
Follow Us
Ironwood Pharma (IRWD)
NASDAQ:IRWD
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.03Last Year’s EPS
-0.03Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: -16.37%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted strong demand growth for LINZESS and promising data for apraglutide, suggesting potential future growth. However, concerns about pricing headwinds from Medicare Part D redesign and cash liquidity tempered the overall outlook.Company Guidance
During the Ironwood Pharmaceuticals Fourth Quarter 2024 Investor Update Conference Call, the company provided guidance for the upcoming year. They expect U.S. LINZESS net sales to range between $800 million and $850 million, forecasting high single-digit prescription demand growth despite potential pricing headwinds due to Medicare Part D redesign. Ironwood anticipates total revenue between $260 million and $290 million and adjusted EBITDA, excluding stock-based compensation, to exceed $85 million. The company aims to complete the NDA submission for apraglutide by the third quarter of 2025, with prelaunch activities underway for its potential commercialization. Ironwood reported $916 million in LINZESS net sales for 2024 and projects its cash flows will support the development and launch of apraglutide, with a focus on delivering sustained profits and reducing debt. The company ended 2024 with $88.6 million in cash and cash equivalents and $385 million in debt, having repaid $115 million over the year.Apraglutide's Potential for Market Expansion
The data from the STARS Extend study showed that 27 patients achieved enteral autonomy, reinforcing apraglutide's potential as a blockbuster therapy for short bowel syndrome. The NDA submission is expected to be completed by the third quarter of 2025.
LINZESS Demand Growth
LINZESS saw a 12% increase in prescription demand growth in Q4 2024 compared to Q4 2023. For the full year 2024, there was an 11% prescription demand growth year-over-year, and new-to-brand volume growth was 14%.
Financial Performance and Guidance
Ironwood achieved its 2024 financial guidance with $916 million in net sales. The company expects continued strong demand growth for LINZESS in 2025, despite anticipated pricing headwinds.
Debt Reduction Efforts
Ironwood reduced its total debt balance by approximately $115 million in 2024, ending the year with $385 million drawn on its credit facility.
---
IRWD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
IRWD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $1.71 | $1.62 | -5.26% |
| Nov 07, 2024 | $5.04 | $4.66 | -7.54% |
| Aug 08, 2024 | $6.01 | $4.05 | -32.61% |
| May 09, 2024 | $8.12 | $6.74 | -17.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Ironwood Pharma (IRWD) report earnings?
Ironwood Pharma (IRWD) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Ironwood Pharma (IRWD) earnings time?
Ironwood Pharma (IRWD) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IRWD EPS forecast?
IRWD EPS forecast for the fiscal quarter 2025 (Q1) is -0.03.
---